^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + HER-2 amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report

    Published date:
    02/26/2021
    Excerpt:
    Transbronchial lung biopsy revealed a moderately differentiated adenocarcinoma (cT4N2M1c, stage IV). An EGFR exon 19 deletion was identified….After the patient was treated with gefitinib initiation (250 mg/d) for 15 months, the tumor progressed with ERBB2 amplification revealed....The combination therapy of afatinib and bevacizumab in this patient was effective with some slight side effects.
    DOI:
    10.1097/MD.0000000000024380